| Document |
Document Title |
|
WO/2016/026841A1 |
The present invention relates to new compounds comprising a siderophore moiety as well as a core structure able to chelate a metal ion. Optionally, the compounds may have additionally a moiety with a functional element including a marker...
|
|
WO/2016/007855A1 |
The total synthesis and evaluation of key analogs of vancomycin containing single atom changes in the binding pocket are disclosed as well as their peripherally modified, N- (hydrophobe-substituted) derivatives exemplified by a N-4- ( 4 ...
|
|
WO/2014/160250A9 |
Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), v...
|
|
WO/2015/184544A1 |
The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem...
|
|
WO/2015/116537A9 |
Described herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting bacterial growth. Methods of using the com...
|
|
WO/2015/145797A1 |
[Problem] The present invention addresses the problem of providing a hemostatic pharmaceutical composition which has higher usability compared with conventional hemostatic agents each utilizing a biogel, and which can be formed into a tr...
|
|
WO/2015/140178A1 |
The present invention relates to a compound of the following formula (I): in which at least one and only one group chosen among R5, R6 and R7 is a group of the following formula: The present invention relates also to uses thereof for pre...
|
|
WO/2015/119180A1 |
The present invention provides: an antibody that has specificity for MUC 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this a...
|
|
WO/2015/085421A1 |
The present disclosure provides glycosylated oligopeptides having the sequence Palmitoyl- X1-Lys-X2-X3-Lys-X4-OH, where: X1 is: absent, Ser having a glycosylated side chain, or Asn having a glycosylated side chain; X2 is: Thr, Thr having...
|
|
WO/2015/084861A1 |
The invention relates to a method for selecting a glycopolypeptide that binds to a target protein, the method including the steps of providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex; combin...
|
|
WO/2015/062168A1 |
Provided is a separation and purification method for vancomycin hydrochloride of a high purity. The method comprises the following steps: (1) obtaining a vancomycin hydrochloride solution from a crude vancomycin product by ion exchange c...
|
|
WO/2015/056011A1 |
A process for the production of a glycoconjugate by N-glycosylation of a protein or peptide comprising the sequence D/E-X-N-X-S/T, wherein each X is the same or different and is any natural amino acid other than proline, wherein the proc...
|
|
WO/2015/024389A1 |
The present invention provides a vancomycin derivative, and a preparation method and an application thereof. The vancomycin derivative of the present invention is obtained by introducing a glyceric acid part between a vancomycin derivati...
|
|
WO/2015/022549A1 |
A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which f...
|
|
WO/2015/022335A1 |
Efforts have thus been made towards the discovery of the next generation of antibiotics to combat the antibiotic resistance in emerging bacterial strains. In spite of these efforts, there remains a need in the art for novel antibiotics a...
|
|
WO/2015/014884A1 |
The invention relates to a fusion protein comprising an antibody directed to Aβ, a monovalent binding entity which binds to a blood brain barrier receptor and a neprilysin.
|
|
WO/2014/175838A1 |
A glycopeptide, comprising a polyproline backbone and one or more carbohydrate molecules.
|
|
WO/2014/162906A1 |
[Problem] The present invention addresses the problem of providing a (sugar chain)-polypeptide complex which can be formed into a transparent and homogeneous hydrogel in a broad pH range. [Solution] The present invention provides a (suga...
|
|
WO/2014/165240A1 |
Synbodies specific for Norovirus and coupled with a substrate provide Norovirus binding and detection platforms (Fig. 1). A Norovirus capturing platform, comprising one or more synbodies selected from the group consisting of synbodies 6-...
|
|
WO/2014/158952A1 |
The present invention relates to a compound of formula I wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; a...
|
|
WO/2014/101294A9 |
The present invention provides a glycopeptide compound or a pharmaceutical salt thereof, as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof. The glycopeptide compoun...
|
|
WO/2014/126787A1 |
Methods are disclosed for increasing the yield and N-glycosylation site occupancy of paucimannose or complex N-glycans of recombinant glycoproteins produced in a recombinant host cell lacking dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl alpha-...
|
|
WO/2013/096697A2 |
In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen, a-xylose or β -xylos...
|
|
WO/2013/072838A1 |
The present invention relates to compounds that are cationic vancomycin analogues and their compositions. Method of making the compounds and their use as medicament for the treatment of bacterial infection are also disclosed.
|
|
WO/2013/068538A1 |
The invention relates to a process for purification of teicoplanin, in particular to a process for an efficient removal of impurities by means of adsorption of particular dissolved components from the filtrate of fermentation broth of Ac...
|
|
WO/2013/068517A1 |
The invention provides an inexpensive process for isolation of teicoplanin from a fermentation culture of Actinoplanes teichomyceticus in a grade for pharmaceutical application with substantial removal of colours. Applying optimal combin...
|
|
WO/2013/034675A1 |
The invention relates to a process for the preparation of telavancin, or a pharmaceutically acceptable salt thereof, wherein said process comprises a reductive alkylation of vancomycin which provides N-protected-decylaminoethylvancomycin...
|
|
WO/2013/034676A1 |
The invention relates to a process for the preparation of telavancin, or a pharmaceutically acceptable salt thereof, wherein said process comprises an alkylation of vancomycin which provides N-protected-decylaminoethylvancomycin-imine, f...
|
|
WO/2012/170491A1 |
Highly specific and novel methods for reversible hydrazone solid-phase extraction (rHSPE) are provided for glycan or glycopeptide isolation from proteins, peptides, and other contaminants for glycan and glycopeptide analysis. Glycans or ...
|
|
WO/2012/142659A1 |
The present invention relates to methods and reagents for use in site-selective modification of proteins and other entities with functionalized peptides using a chemoenzymatic sortase mediated reaction. The functionalized entities may be...
|
|
WO/2012/139777A1 |
The present invention relates to a method for the production of a glycosylated peptide comprising providing a peptide conjugated with one or more hydrophilic polymer(s) and glycosylating the polymer-conjugated peptide by means of one or ...
|
|
WO/2012/123926A1 |
The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n are as defined in claim 1.
|
|
WO/2012/094627A2 |
Provided herein are methods and recombinant expression systems for the production of recombinant glycoproteins that have increased sialic acid content and contain predominantly alpha2-6 sialic acid linkages. Also provided herein are reco...
|
|
WO/2012/085221A1 |
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularl...
|
|
WO/2012/027850A1 |
Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in C. jejuni. The GlycoTag peptide can be in a purified and isolated form following exp...
|
|
WO/2011/156751A2 |
A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine.
|
|
WO/2011/145055A1 |
The invention relates to novel cyclodecapeptide compounds having formula (I) for use as drugs and, more specifically, for use in the diagnosis, prevention and/or treatment of neurodegenerative diseases, such as Wilson's disease and Alzhe...
|
|
WO/2011/140009A1 |
Methods of using semi-synthetic glycopeptides of formula I-XIV having antibacterial activity are described.
|
|
WO/2011/097733A1 |
An isolated or purified compound is provided, comprising A- GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GIcNAc or GIc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an inf...
|
|
WO/2011/047097A2 |
The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-I and TREM-2. Mor...
|
|
WO/2011/047047A2 |
This document provides methods and materials related to composites or coatings containing polypeptides attached to polysaccharides and/or molecules. For example, methods and materials related to composites or coatings containing polypept...
|
|
WO/2011/011879A1 |
Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a α1,6-glucan-containing Helicobacter pylori compound...
|
|
WO/2011/007764A1 |
Disclosed is a sugar chain marker which can detect hepatic diseases. More specifically disclosed is a sugar chain marker which can be used as a measure of the disease conditions of hepatic diseases. Further specifically disclosed is a su...
|
|
WO/2011/005959A1 |
Compounds useful in the preparation of telavancin, for example, were prepared. These compounds include decylaminoethanal dialkyl acetals and N-protected decylaminoethanal dialkyl acetals, imidazolidine derivatives, and N-protected- decyl...
|
|
WO/2010/150558A1 |
It is possible to easily and effectively produce an intentionally designed glycopeptide. For this, disclosed is a method for producing a modified peptide in which at least one amino acid residue capable of binding to a sugar is modified ...
|
|
WO/2010/117753A2 |
Oral care compositions, oral care systems, oral surface-binding peptides, and a method for applying particles to an oral surface are provided. The oral care system comprises at least one peptidic component comprising a first binding elem...
|
|
WO/2010/113035A2 |
Beta-mimetic compositions and methods of making and using such compositions in preparing bioactive peptides, such as antimicrobial peptides, are disclosed. In particular, spirocyclic proline hybrids are provided that may be used to alter...
|
|
WO/2010/108040A1 |
Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identif...
|
|
WO/2010/089341A1 |
The present invention relates to novel vancomycin-aminoquinoline hybrid molecules designated "vancomyquines®", preparation thereof and application thereof in therapeutics. The present invention notably relates to novel hybrid molecules ...
|
|
WO/2010/068817A1 |
Provided are lectenz molecules, which are mutated carbohydrate processing enzyme enzymes that are catalytically inactive and that have had their substrate affinity increased by at least 1.2 fold. Further provided are methods for making a...
|
